Form 4: Revolution Medicines GC Sells Shares Under 10b5-1 Plan

Revolution Medicines General Counsel Jeff Cislini sold 1,799 shares of common stock for $44.26 per share pursuant to a pre-arranged 10b5-1 trading plan.

Summary

• Jeff Cislini, General Counsel of Revolution Medicines, Inc. (RVMD), reported a sale of common stock.
• The transaction involved 1,799 shares of common stock.
• The shares were sold at a price of $44.26 per share.
• The total value of the shares sold was approximately $79,623.74.
• The sale was executed on September 24, 2025.
• This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Cislini on March 13, 2025.
• Following this transaction, Mr. Cislini beneficially owns 50,425 shares, which includes 43,910 restricted stock units.

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-scheduled insider stock sale under a 10b5-1 plan. This type of transaction is generally considered neutral as it does not reflect new information about the company's performance or prospects, but rather a personal financial management decision by an executive.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction rather than a reaction to recent company news, which can mitigate concerns about insider trading.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by some investors, though the amount in this instance is relatively small.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing reports a routine insider transaction for Revolution Medicines, a biotechnology company. Such transactions are common across the industry, particularly when executed under Rule 10b5-1 plans, which allow insiders to sell shares at pre-determined times to avoid accusations of trading on material non-public information. It does not provide specific insights into broader industry trends or competitive positioning.

Comparison to Industry Standards

• This is a standard Form 4 filing reporting an insider stock transaction.
• The use of a 10b5-1 plan aligns with best practices for corporate governance in the biotechnology and pharmaceutical industries, demonstrating an effort to mitigate concerns about insider trading.
• No specific comparable companies, projects, or results are relevant for this type of filing as it pertains to an individual's personal stock management.

Stakeholder Impact

• Shareholders: Minor impact. A small, pre-planned insider sale typically does not significantly alter investor sentiment or the company's valuation.
• Employees, Customers, Suppliers, Creditors: No direct impact from this specific filing.

Key Dates

Keywords

Revolution Medicines, RVMD, Jeff Cislini, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, General Counsel, Biotechnology, Pharmaceuticals